Insight Innovation: Die riskante Wette auf den ersten Impfstoff gegen Krebs
Hautkrebs könnte bald mit demselben Prinzip bekämpft werden, mit dem schon das Coronavirus gebändigt wurde. Moderna und Merck melden Erfolge mit einem mRNA-Impfstoff. Doch es gibt Hürden.
Munich's Moderna achieved its first major breakthrough in 2021 amid the raging Covid-19 pandemic. CEO Stéphane Bancel announced promising test data for a Covid-19 vaccine. Five years later, Moderna is targeting a new medical milestone, this time against cancer, a riskier and costlier bet for the US biotech company. The world of pharmaceuticals looked skeptical at the start, but Moderna surprised everyone with positive test results for an innovative skin cancer vaccine on Wednesday last week.
The company is developing the drug in collaboration with US pharmaceutical giant Merck & Co*. This is the first drug based on messenger RNA (mRNA) technology to show promise against cancer in a large, approval-relevant study. The drug could hit the market by 2027. Experts and analysts are calling it a scientific breakthrough. Wall Street analysts expect billion-dollar sales, and tech investors are impressed. Could the same principle used to combat coronavirus now be used to fight skin cancer?
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Insight Innovation: The Risky Bet on the First Cancer Vaccine handelsblatt.com
